2025
diAcCA, a Pro-Drug for Carnosic Acid That Activates the Nrf2 Transcriptional Pathway, Shows Efficacy in the 5xFAD Transgenic Mouse Model of Alzheimer’s Disease
Banerjee P, Wang Y, Carnevale L, Patel P, Raspur C, Tran N, Zhang X, Natarajan R, Roberts A, Baran P, Lipton S. diAcCA, a Pro-Drug for Carnosic Acid That Activates the Nrf2 Transcriptional Pathway, Shows Efficacy in the 5xFAD Transgenic Mouse Model of Alzheimer’s Disease. Antioxidants 2025, 14: 293. PMCID: PMC11939361, DOI: 10.3390/antiox14030293.Peer-Reviewed Original ResearchAlzheimer's diseaseNrf2 transcriptional pathwayTranscriptional pathwaysAmyloid plaque formationMouse model of Alzheimer's diseaseTransgenic mouse model of Alzheimer's diseaseModel of Alzheimer's diseaseAD transgenic miceCorrelated to cognitive declineNeuritic aggregatesTau tanglesAmyloid plaquesPhospho-tauCarnosic acidSynapse lossHuman ADPurified CATransgenic mouse modelPhenolic diterpenesAmyloidMicroglial inflammationPathwayPlaque formationTransgenic miceNrf2
2022
Towards development of disease-modifying therapy for Alzheimer's disease using redox chemical biology pathways
Lipton S. Towards development of disease-modifying therapy for Alzheimer's disease using redox chemical biology pathways. Current Opinion In Pharmacology 2022, 66: 102267. PMID: 35870288, PMCID: PMC9509422, DOI: 10.1016/j.coph.2022.102267.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseDisease-modifying therapiesPotential therapeutic efficacySevere side effectsPotential therapeutic targetCerebral organoid modelTranscription factor Nrf2Absence of diseaseNMDA typeGlutamate receptorsDisease processSide effectsTherapeutic targetTransgenic miceTherapeutic efficacyNeurodegenerative disordersNormal tissuesDiseaseFactor Nrf2Organoid modelsProtein S-nitrosylationS-nitrosylationProtein Keap1TherapyNrf2
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply